Myomo Inc. · AMEX:MYO

Myomo — Investor Presentation (November 2026)

19 slides from Myomo's investor presentation, November 2026

  1. Slide 1: Investor Presentation November 2026

    INVESTOR PRESENTATION NOVEMBER 2026 Paul R. Gudonis, Chairman and CEO David Henry, Chief Financial Officer Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Compan

  3. Slide 3: Investment Highlights

    Investment Highlights Created New Product First-Mover Advantage Category for a Large, with Strong Competitive Unmet Need Position Medicare Reimbursement Growing Revenues from Attractive Margin Profile and New Payer Contracts Recurring Patient with Opportunity for Scale Expanding Patient Access Sourc

  4. Slide 4: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease

    Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI ➢ Stroke/CVA ➢ Cerebral Palsy ➢ Traumatic Brain BPI ➢ Multiple Sclerosis Injury PI ➢ ALS ➢ Spinal Cord Injury ➢ Spinal Muscular ➢ Brachial Plexus Atrophy Injury ➢ Acute Flaccid Myelitis 4

  5. Slide 5: Patient Journey: From Stroke to Rehab Therapy

    Patient Journey: From Stroke to Rehab Therapy ONSET ACUTE SUB-ACUTE OUTPATIENT CHRONIC CARE CARE THERAPY HEMIPARESIS Incidence: (Incidence) (Prevalence) 800,000 Onset → 1 week 1 week → 6 6–12 months > 6–12 months Cases/Yr. months in US Patients are told “Get used to it – You’ll never use your arm an

  6. Slide 6: Multi-Billion Dollar Market Opportunity @ $55K ASP

    Multi-Billion Dollar Market Opportunity @ $55K ASP 40,000 to Senior Insured Population 400,000 to 80,000 patients 800,000 replenish the 45% patients may prevalence qualify for a 55% population MyoPro each year Surviving patients that Medicare Part B Med. Advantage also carry appropriate insurance So

  7. Slide 7: U.S. Market Size

    Company Goal: Market Penetration Expand MyoPro adoption to address a large unmet need: US market 400,000 – 800,000 Potential MyoPro candidates with Chronic Arm Paralysis in Prevalence Population U.S. market size ANNUAL INCIDENCE 40,000 - 80,000 New cases per year after post- stroke therapy CURRENT P

  8. Slide 8: Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living

    Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living 7

  9. Slide 9: How it Works: Myomo's Proprietary Technology

    How it Works: Myomo’s Proprietary Technology ➢ Brain-computer interface ➢ Interpret and amplify a patient’s weak EMG signal ➢ 35 Patents in U.S. and International markets valid through 2042. 9

  10. Slide 10: Myomo Mobility Platform: Technology and Commercial Infrastructure

    Myomo Mobility Platform: Technology and Commercial Infrastructure Geographic Markets US Germany OUS Note: TBD Indications Stroke TBI SCI BPI Other Product MyoPro 3 Next - Gen MyoPro MyoPal Development Product Family Hand Pediatric Current MyoPro 2X MyoPro2X MARK Connected Training Products Motion G

  11. Slide 11: Go to Market Approach Via Distribution Channels

    Go to Market Approach Via 3 Distribution Channels Stroke TBI Orthotics & Direct-to-Patient Referrals from Advertising SCI Rehab Hospitals Prosthetics (Social Media/TV) (MyoConnect) Clinics BPI PI ------------ Recurring Patient Sources ------------ 11

  12. Slide 12: Now Over 500 MyoConnect Referring Facilities

    Now Over 500 MyoConnect Referring Facilities Over 500 rehab hospitals and stroke clinics referring patients for a MyoPro Growing number of facilities referring multiple patients 12 Expanding Myomo’s commercial operations field staff Therapist Referrals Physician Referrals 12

  13. Slide 13: Insurance Reimbursement Supported by Clinical Research

    Insurance Reimbursement Supported by Clinical Research Subjects from our Stroke Patient Registry TBI SCI Blue Cross Blue Shield logo. BPI Systematic PI review published in 2025 German Statutory Health Insurance US Department of Veterans Affairs seal and name. Randomized Controlled Trial underway Med

  14. Slide 14: 2026 Strategy Direction & Four Success Pillars

    2026 Strategy Direction & Four Success Pillars 1. Shift to Recurring Patient Sources 3. Demonstrate operating leverage Recurring Patient Sources Revenue Growth vs. Opex Growth Q3 2026: Revenue 22% Opex 6% GM 750 bps 2. Increase market access with additional 4. Invest in product development and resea

  15. Slide 15: Track Record: 10 Years of Revenue Growth

    Track Record: 10 Years of Revenue Growth Revenues Recurring $M Launched Patient MyoConnect Sources + O&P 46-47 Channel Medicare 40.9 Part B revenues 32.6 U.S and Record Int’l Int’l Expanded # and VA Growth of Payers Revenue Pivot to and VAMC’s 19.2 Direct Billing, 15.6 Higher ASP; 13.9 Commercial HC

  16. Slide 16: P&L and Key Balance Sheet Metrics

    P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual YTD YTD ($000's) Q3'26 Q3'25 2026 2025 Actual Actual ($000's) Q3'26 Q2'26 Revenue 12,330 10,091 34,148 29,575 COGS 3,540 3,648 10,014 10,471 Cash & Investments $ 11,946 $ 13,452 Gross Profit 8,790 6,443 24,134 19,104 Worki

  17. Slide 17: Where We're Headed: Longer-Term Vision

    Where We’re Headed: Longer-Term Vision Revenue Revenue Growth Catalysts 120 Stroke $M 100 TBI How We Get There • RCT • Additional payer 80 contracts 60 SCI • MyoPro 3 40 BPI • Hand-Only • Mobile App 20 PI 0 Same-store sales 2025 Future growth based on patient outcomes ➢ > $100M in annual revenues ➢

  18. Slide 18: Leadership Team & Board of Directors

    Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Thomas Kirk John Frijters Chairman & CEO Managing Director - Lead Independent Director Scaled multiple tech co’s, largest from Former CEO, Hanger Clinics International $5M to $1.2B revenue (BBN/Genuity) T

  19. Slide 19: Thank You! For Additional Information

    Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 19

Myomo — Investor Presentation (November 2026) on 6ix